

IPSEN

YTD 2023 HIGHLIGHTS


FOCUS. TOGETHER.
FOR PATIENTS & SOCIETY.

Our portfolio has performed well across the three therapy areas, driven by strengthened commercial execution and the results of our external-innovation strategy.

Further good news from the pipeline continue to provide additional options for patients with real unmet medical needs. In the final quarter of the year, we look forward to sharing further details on sustainable growth opportunities across our portfolio and pipeline at our forthcoming capital-markets day.

David Loew
CEO

YTD 2023 TOTAL SALES




■ Oncology
■ Rare Disease
■ Neuroscience

FY 2023 GUIDANCE REITERATED

Total-sales growth
greater than 6.0%
(at constant exchange rates)


Core operating margin
greater than 30% of total sales

GROWTH PLATFORMS | NEW MEDICINES



GEOGRAPHIC BREAKDOWN

YTD 2023 TOTAL SALES BY REGION



PIPELINE UPDATE

Sohonos: U.S. FDA approval of Sohonos (palovarotene): fibrodysplasia ossificans progressiva

Bylvay: resubmission to the EMA under a new brand name for the treatment of ALGS by the end of 2023

Cabometyx + atezolizumab: progression-free survival primary endpoint met: second-line metastatic castration-resistant prostate cancer

All growth rates are at constant exchange rates.

¹North America only, excludes sales to ex-U.S. partner.

YTD: nine months to September; FDA: Food and Drug Administration; EMA: European Medicines Agency; ALGS: Alagille syndrome.

For further information on Ipsen's YTD 2023 sales update and definitions of financial indicators, please refer to the press release at:

www.ipsen.com/investors

Craig Marks

Vice President, Investor Relations
+44 7584 349 193
craig.marks@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations
+33 6 52 19 98 92
nicolas.bogler@ipsen.com

IPSEN
Innovation for patient care